In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in ...

According to Future Market Insights, myelofibrosis (mf) treatment market is expected to grow at a CAGR of 5.5% between 2023 and 2033, reaching USD 1,280 Million by 2033. The market is expected to ...

Also in December, Takeda paid $200 million upfront for Keros’ activin inhibitor elritercept, which is being developed to treat anemia seen in blood cancers. In February, the biotech said it ...

The PD-1 inhibitor, originally approved in 2019 ... Key Phase 3 investigational drugs include itepekimab (IL-33, COPD), garetosmab (activin A, fibrodysplasia ossificans progressiva), and fianlimab ...

Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...

Merck's stock rose 2% Monday on the back of positive data from a study of a new hypertension drug. MRK stock has declined 7% so far this year, compared to a 5.7% increase for the wider ...

The "overwhelming efficacy" seen with the activin signalling inhibitor in the study has led the investigators to stop it early, allowing all patients to receive Winrevair as part of an open-label ...

ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E ... rise of Novo Nordsk’s GLP1 inhibitor, Wegovy. However, elsewhere in the ...